## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.6% in upper entry zone (3.0-6.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Strong momentum (+3.9% 5-day acceleration). Outperforming sector by 4.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($708.17)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T143458 | Bullish | Relevance: 100%
- Woodstock Corp significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 107.1% during the third quarter, purchasing an additional 8,589 shares to own 16,610 shares valued at $9.34 million. This move comes amidst mixed insider activity, with significant sales by a director and a VP, while institutional ownership remains high at 83.31%. Analysts have a "Moderate Buy" rating on REGN with an average price target of $779.45.

**2. Sicart Associates LLC Makes New $3.93 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T123820 | Somewhat-Bearish | Relevance: 100%
- Sicart Associates LLC has made a new investment of $3.93 million in Regeneron Pharmaceuticals (NASDAQ:REGN) during the third quarter of 2025, acquiring 6,981 shares. This comes as Regeneron outperformed quarterly estimates, and analysts have issued a "Moderate Buy" consensus with an average price target of $779.45. Despite some insider selling, institutional investors now own 83.31% of the company's stock.

**3. Leerink Partners raises Regeneron stock price target to $873 on growth outlook**
- Source: Investing.com | 20251217T100843 | Bullish | Relevance: 100%
- Leerink Partners has increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $873 from $710, maintaining an Outperform rating due to strong growth prospects. This revised outlook is driven by anticipated 11% five-year compound annual growth in EPS, primarily fueled by EYLEA HD's projected success and positive updates on Dupixent. The new target is based on an 18.0x multiple applied to Leerinkâ€™s 2027 diluted EPS estimate, reflecting differentiated growth compared to industry peers.

**4. Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Assenagon Asset Management S.A.**
- Source: MarketBeat | 20251217T090841 | Bullish | Relevance: 100%
- Assenagon Asset Management S.A. increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 12.9% in the third quarter, now owning 477,810 shares valued at approximately $268.66 million. Regeneron Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with EPS of $11.83 and revenue of $3.75 billion, and maintains a "Moderate Buy" consensus rating among analysts. Insider transactions show recent sales by a director and a VP, while institutional investors collectively hold 83.31% of the company's stock.

**5. Is Regeneron Still Attractively Priced After Its Recent Share Price Surge?**
- Source: Simply Wall Street | 20251217T023440 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals has seen a recent share price surge but a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 53.1%. Additionally, its Price to Earnings (PE) ratio of 16.73x is below both the biotech industry average and its proprietary Fair Ratio, further indicating undervaluation based on company-specific fundamentals. The article encourages investors to use "Narratives" on Simply Wall St to align their views with financial data for a more personalized valuation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.5B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 19.5 |
| Current P/E | 17.4 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.8% to 5.6% (+3.9% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 89th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. Outperforming sector by 4.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-3.02), momentum weakening. RSI neutral at 60. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.64% (CS: 90) | Strong |
| RSI_14 | 60.0 | Neutral |
| MACD Histogram | -3.02 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.118x | Above |
| vs SMA200 | 1.249x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $749.79
- **Stop Loss:** $708.17 (5.6% risk)
- **Target:** $812.22 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $18,744.75
- **Portfolio %:** 18.74%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*